Collegium Pharmaceutical Files 8-K

TL;DR

Collegium Pharma filed an 8-K, mostly standard stuff with exhibits.

AI Summary

On April 11, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a routine update rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This 8-K filing serves as a public record of Collegium Pharmaceutical's submitted documents to the SEC, ensuring transparency for investors and stakeholders.

Risk Assessment

Risk Level: low — The filing appears to be a routine submission of financial statements and exhibits, not indicating any immediate or significant risks.

Key Players & Entities

• COLLEGIUM PHARMACEUTICAL, INC. (company) — Registrant
• April 11, 2024 (date) — Date of Report
• Virginia (jurisdiction) — State of Incorporation
• 001-37372 (company_id) — SEC File Number
• 100 Technology Center Drive Suite 300 (address) — Principal executive offices
• Stoughton, MA 02072 (address) — Principal executive offices
• ( 781 ) 713-3699 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
• $26,350,000 — 99.1, announcing that it has called all $26,350,000 aggregate principal amount of its outst

Filing Documents

• tm2411583d1_8k.htm (8-K) — 25KB
• tm2411583d1_ex99-1.htm (EX-99.1) — 11KB
• tm2411583d1_ex99-1img001.jpg (GRAPHIC) — 13KB
• tm2411583d1_ex99-1img002.jpg (GRAPHIC) — 10KB
• 0001104659-24-046091.txt ( ) — 231KB
• coll-20240411.xsd (EX-101.SCH) — 3KB
• coll-20240411_lab.xml (EX-101.LAB) — 33KB
• coll-20240411_pre.xml (EX-101.PRE) — 22KB
• tm2411583d1_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On April 11, 2024, Collegium Pharmaceutical, Inc. (the "Company") issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes due 2026 (the "Notes") for redemption on June 14, 2024 (the "Redemption Date"). The redemption price will be equal to 100% of the principal amount of each Note called for redemption, plus accrued and unpaid interest on such Note to, but excluding, the Redemption Date for such Note (the "Redemption Price"). Notes called for redemption may be surrendered at any time before 5:00 p.m., New York City time, on June 13, 2024 (or, if the Company fails to pay the Redemption Price due on the Redemption Date in full, at any time until such time as the Company pays such Redemption Price in full) (the "Conversion Deadline"). The Company has elected to settle all conversions of Notes between now and the Conversion Deadline in cash. This Current Report on Form 8-K is not a notice of redemption of the Notes. The redemption is being made solely pursuant to the Notice of Redemption, dated April 11, 2024, relating to the Notes.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated April 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 11, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR